Recipharm notches up two more niche CDMO acquisitions

The two transactions enable Recipharm to expand its ATMP offering into virotherapies and boost its US biologics services

The Swedish CDMO has made no secret about its strategy to strengthen its service offerings in new biologic modalities, and its acquisition of Vibalogics — a virotherapy CDMO — backs that.

To keep pace with the rapidly growing demand from Big Pharma, mid-sized biotechs and start-ups for specialised CDMO manufacturing of live viruses and viral vectors, Vibalogics recently invested in expansions in Germany and the US to enable it to support the full product lifecycle of its clients, including commercial supply.

The deal will provide Recipharm with capabilities in new biologics modalities, leveraging Vibalogics’ expertise in oncolytic viruses, viral vaccines, and viral vector gene therapies to bring a high degree of diversification across multiple technologies and modalities.

Arranta Bio, Recipharm's second purchase, brings to the table a strong service portfolio in delivering microbiome therapeutic products and mRNA clinical production capabilities.

The company Arranta has established a strong microbiome platform with fermentation and purification expertise for naturally derived and engineered bacteria consortia, complemented by services in analytics, proprietary media and cryopreservative formulations.

These services are reported to maximise yields and enhance viability for live biotherapeutic products that clients are testing in the clinic against a range of infectious, inflammatory, neurological and oncological diseases.

This acquisition, therefore, establishes a robust US presence for Recipharm, providing it with a further platform from which to build its capabilities in new biologics modalities, leveraging Arranta’s expertise in advanced therapies to bring a high degree of diversification across multiple technologies and modalities.